

in classes IX to XII. All these schools, which are part of the first phase of the project, will be affiliated to Delhi Board of School Education (DBSE).

Presiding over the second general body meeting of SoSE and DBSE on Tuesday, education minister Manish Sisodia made the announcement. TOI had first reported about the move on July 21, after the Delhi cabinet had, in March, approved the project.

and mathematics (sciences, performing and visual arts, and high-end 21st century skills. The government is partnering with Australian Council for Educational Research and Boston Consulting Group to implement the project.

Among the 20, eight schools will specialise in science, technology, engineering and maths, five in humanities and high-end 21st century skills, and two in performing and visual arts.

which will enable them to join some of the best universities in the country and abroad

In two years, around 100 schools will be set up covering domains in every educational in Delhi so that children across the city can access specialised schools in their neighbourhood.

"Students at SoSEs will r

# City pharma varsity's ayurvedic Covid drug awaits Ayush nod

Shradha.Chettri@timesgroup.com

**New Delhi:** Delhi Pharmaceutical Sciences and Research University, a state university, has developed a Covid drug called "Coroquil-Zn". It is now waiting for the approval from Ministry of Ayush. It has already been granted a licence for manufacturing and sales by the Chennai state licensing authority.

According to Ramesh K Gopal, vice-chancellor of the university, this is the first-of-its-kind repurposed ayurveda drug.

"The drug has been developed by the university in collaboration with Remedium Therapeutics Pvt Ltd, Chennai. Coroquil-Zn has been granted the licence for manufacturing and sales by Jammi Pharmaceuticals Pvt Ltd, Chennai. Clinical trials phase-3 study for capsules got completed at Sri Lakshmi Super Specialty Hospital, Bengaluru in mild and moderate Covid-19 patients as per the Ayush and ICMR guidelines for pandemic trials," said Goyal. The patients were in the



**AYURVEDIC ANTIVIRAL**

age group of 23 to 75 years old.

The drug is formulated using edible plant ingredients, which were identified by CR Babu, professor emeritus and head of the Centre for Environmental Management of Degraded Ecosystem at Delhi University at Aravalli Biodiversity Park.

"LG Anil Baijal, chancellor of the university, encouraged us to work towards this. Coroquil-Zn modulated ACE-2 receptors of SARS-COV-2 and can prevent and treat the patients of Covid-19 and prevent post-Covid complications," said Goyal.

A study carried out by Dr Kamlesh Singh at University of Missouri helped the varsity work towards developing the drug.

The clinical trial was conducted in 120 patients to assess the safety and efficacy of the drug. "The results of clinical studies showed that Coroquil-Zn treatment produced a significant reduction in viral load. It showed 46%, 89% and 100% patients being RT-PCR negative on 5th, 7th and 14th day of treatment, as compared to 6%, 44% and 89%, respectively, in the standard care group. It highlighted a distinct clinical improvement in the severity of dyspnea and recovery rate," added Goyal.

According to the university, among those who had taken the drug, the oxygen saturation level was good throughout the treatment. The patients showed no adverse effects. "Patients also recovered their taste and smell within eight days of consuming the drug. They got discharged from the hospital sooner than standard care patients," added Goyal.

## Call centre busted

A call centre, running under the garb of a customer care service centre of an automobile company, was busted in Rohini on Tuesday. Seven employees, including a woman, have been arrested. Cops



### NATIONAL LAW INSTITUTE UNIVERSITY

Kerwa Dam Road, Bhopal-462044, M.P. (INDIA)

Applications are invited for admission to the Two Years Master of Cyber Law and Information Security Programme for the Academic Session 2021-22.

For other details please visit University website :





# Delhi's Pharma University nears landmark; Makes breakthrough Ayurvedic treatment for Covid-19

By: Subham Mitra | July 28, 2021 12:38 PM

According to DPSRU Vice-Chancellor Prof Ramesh K. Goyal, Coroquil-Zn is the first formulation that modulates the SARS-Cov-2 virus' ACE-2 levels and/or receptors, enabling it to prevent and treat Covid-19 symptoms and prevent post-Covid complications.



Advertisement



**FINANCIAL EXPRESS**  
Read to Lead

**Biz News & Updates**

DELIVERED INSTANTLY TO YOUR PHONE

Join Our Telegram Channel

t.me/TheFinancialExpressOnline

## This new ayurvedic drug reduces viral load in Covid patients

— July 27, 2021



*Prof Ramesh K Goyal*

**Rohit Shishodia**

Delhi Pharmaceutical Sciences and Research University (DPSRU) has developed COROQUIL-Zn-- an Ayurveda drug which effectively reduces viral load in Covid patients.

“The results of clinical studies showed that COROQUIL-Zn treatment produces a significant reduction in viral load (46%, 89%, and 100% patients becoming RT-PCR negative on 5th, 7th and 14th day of treatment as compared to 6%, 44%, and 89%, respectively in the standard of care group) with a distinct clinical improvement in the severity of dyspnea and recovery rate,” DPSRU said in a press statement.

Speaking to DTMT, Prof Ramesh K Goyal, Vice Chancellor, DPSRU, said that the drug will also be effective in the delta variant of Covid.

“The drug also helps in management of post Covid complications,” he added.

He said that the drug is yet to get the final approval of Indian Ministry of Ayush for its availability in market. The formulation, which has been developed in association with Remedium Therapeutics Pvt Ltd, Chennai, has been granted the licence for manufacturing and sales by Jammi Pharmaceuticals Pvt Ltd.



## Delhi pharma varsity's ayurvedic Covid drug awaits Ayush nod

### ARTICLES

Delhi pharma varsity's ayurvedic Covid drug awaits Ayush nod

JNU entrance exam to be held from Sept 20; registration start...

Flipkart! A chosen destination for all smartphone needs

Covid-19: 77 new cases in Delhi as positivity rate up a tad to 0.11%



ffff

NEW DELHI: Delhi Pharmaceutical Sciences and [Research University](#), a state university, has developed a Covid drug called "Coroquil-Zn". It is now waiting for the approval from [Ministry of Ayush](#). It has already been granted a licence for manufacturing and sales by the Chennai state licensing authority.